Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19 t-haNK in Relapsed/Refractory DLBCL
NCT04052061Phase 1Withdrawn
- Sponsor
- ImmunityBio, Inc.
- Start
- Sep 2019
- Primary completion
- Sep 2021
- Modality
- Gene Editing, Gene Silencing, Lymphokine-Activated Killer Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CD19t-haNK in diffuse large B-cell lymphoma (DLBCL), sponsored by ImmunityBio, Inc. Primary endpoints: Maximum Tolerated Dose at 1 year, Recommended Phase 2 Dose at 1 year and 2 more. Planned start Sep 2019; status: withdrawn.
02
Drugs
CD19t-haNK
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT04052061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04052061.